Prostate-specific antigen testing in men aged 40-64 years: Impact of publication of clinical trials

Journal of the National Cancer Institute

Volumn 105, Issue 10, 2013, Pages 743-745

  Goodwin, James S ^a   Tan, Alai ^a   Jaramillo, Elizabeth ^a   Kuo, Yong Fang ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SCREENING; CLINICAL TRIAL (TOPIC); ETHNICITY; HEALTH CARE ORGANIZATION; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN TESTING; PUBLICATION; RACE; SCREENING;

ADULT; CLINICAL TRIALS AS TOPIC; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 84877993796     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt039     Document Type: Article

References (17)

1. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results form a randomized prostate-cancer screening trial. N Eng J Med. 2009;360:1310-1319.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
3. Brown M. AAFP, USPSTF Issue Final Recommendation Against Routine PSA-Based Screening for Prostate Cancer. http://www.aafp.org/online/en/home/ publications/news/news-now/health-of-the-public/20120522psascreenrec.html. Accessed January 18, 2013.
4. Hoffman RM. Screening for Prostate Cancer. http://www.uptodate.com/ contents/screen-ing-for-prostate-cancer?source=search-result &search=screening+for+prostate+cancer&sel ectedTitle=1~150. Accessed January 17, 2013.
5. Wolf AMD, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin.2010;60(2):70-98.
6. Optum Clinformatics Datamart. http://www.optuminsight.cm/life-sciences. clinformatics-data. Accessed December 12, 2012.
7. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Statistics in Medicine 2000;19:335-351: (correction 2001;20:655).
8. Joinpoint Regression Program, version 3.5. Bethesda, MD: Statistical Methodology and Applications Branch and Data Modeling Branch, Surveillance Research Program, National Cancer Institute; 2011.
9. US. Department of Commerce, Bureau of the Census. Census Bureau Regions and Divisions with State FIPS Codes. http://www.census.gov/geo/www/reg-div.txt. Accessed December 6, 2012.
10. Nattinger AB, Hoffman RG, Howell A, Goodwin JS. Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women. JAMA. 1998;279(10):762-766.
11. Giordano SH, Duan ZG, Kuo YF, Hortobagyi GN, Fremean JL, Goodwin JS. Impact of a scientific presentation on community treatment patterns for primary breast cancer. J Natl Cancer Inst. 2006;98(6):382-388.
12. Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1): 71-78.
13. Yasmeen S, Romano PS, Tancredi DJ, Saito NH, Rainwater J, Kravitz RL. Screening mammography beliefs and recommendations: a Web-based survey of primary care physicians. BMC Health Ser Res. 2012:12:32.
14. Davis K, Haisfield L, Dorfman C, Krist A, Taylor KL. Physicians' attitudes about shared decision making for prostate cancer screening. Fam Med. 2011;43(4):260-266.
15. Pollack CE, Noronha G, Green GE, Bhavsar NA, Carker HB. Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. Arch Intern Med. 2012;172(8):668-669.
16. Zeliadt SB, Hoffman RM, Etzioni R, Gore JL, Kessler LG, Lin DW. Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst. 2011;103(6):520-523.
17. Ross JS, Wang R, Long JB, Gross C P, Ma X. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med. 2012;172(20):1601-1603.